Answers are grounded in this paper and cite their sources.
The prognostic score we developed may be useful in designing clinical trials for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics.
No takes yet. Share an insight, caveat, or question.
Hasenclever et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: